LISATA Trademark

Trademark Overview


On Friday, April 22, 2022, a trademark application was filed for LISATA with the United States Patent and Trademark Office. The USPTO has given the LISATA trademark a serial number of 97377210. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Wednesday, December 4, 2024. This trademark is owned by Caladrius Biosciences, Inc.. The LISATA trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for use in cancer, tumors, diabetic kidney disease, coronary microvascular dysfunction, Buerger's Disease, and Critical Limb Ischemia; Pharmaceutical preparations for use in treating and managing diseases, disorders, and conditions involving oncology, cardiology, vascular system, and ischemia; Therapeutic pharmaceutical preparations for enhancing the targeting, delivery, and effectiveness of cancer treatments; Therapeutic agents for promoting ischematic repair, regenerating damaged tissue, stimulating the repair or growth of microvasculature, penetrating tissue surrounding tumors, and altering immunosuppressive tumor microenvironments

Research and development in the fields of pharmaceuticals, biotechnology, cell therapies, drug delivery technologies, oncology, cardiology, vascular system, and ischemia; Providing medical scientific information in the fields of pharmaceuticals, biotechnology, cell therapies, drug delivery technologies, oncology, cardiology, vascular system, and ischemia; Drug discovery services
lisata

General Information


Serial Number97377210
Word MarkLISATA
Filing DateFriday, April 22, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateWednesday, December 4, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 18, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for use in cancer, tumors, diabetic kidney disease, coronary microvascular dysfunction, Buerger's Disease, and Critical Limb Ischemia; Pharmaceutical preparations for use in treating and managing diseases, disorders, and conditions involving oncology, cardiology, vascular system, and ischemia; Therapeutic pharmaceutical preparations for enhancing the targeting, delivery, and effectiveness of cancer treatments; Therapeutic agents for promoting ischematic repair, regenerating damaged tissue, stimulating the repair or growth of microvasculature, penetrating tissue surrounding tumors, and altering immunosuppressive tumor microenvironments
Translation of Words in MarkThe English translation of "LISATA" in the mark is "AUGMENT".
Goods and ServicesResearch and development in the fields of pharmaceuticals, biotechnology, cell therapies, drug delivery technologies, oncology, cardiology, vascular system, and ischemia; Providing medical scientific information in the fields of pharmaceuticals, biotechnology, cell therapies, drug delivery technologies, oncology, cardiology, vascular system, and ischemia; Drug discovery services

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 28, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, April 28, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameLISATA THERAPEUTICS, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressBASKING RIDGE, NJ 07920

Party NameCaladrius Biosciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBasking Ridge, NJ 07920

Party NameCaladrius Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBasking Ridge, NJ 07920

Trademark Events


Event DateEvent Description
Thursday, February 16, 2023NON-FINAL ACTION E-MAILED
Tuesday, April 26, 2022NEW APPLICATION ENTERED
Thursday, April 28, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 9, 2023ASSIGNED TO EXAMINER
Thursday, February 16, 2023NON-FINAL ACTION WRITTEN
Thursday, February 16, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 3, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 3, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 3, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 13, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 18, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 18, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, November 10, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, June 13, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, November 10, 2023SOU EXTENSION 1 FILED
Friday, November 10, 2023SOU EXTENSION 1 GRANTED
Tuesday, November 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 20, 2024SOU EXTENSION 2 GRANTED
Monday, May 20, 2024SOU EXTENSION 2 FILED
Wednesday, December 4, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, December 4, 2024SOU EXTENSION 3 FILED
Thursday, December 5, 2024SOU EXTENSION 3 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 22, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Monday, May 20, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, May 21, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED